- C-Ray Therapeutics has received Full Accreditation from AAALAC International for its laboratory animal care and research practices.
- The accreditation covers the company’s 28,000-square-meter integrated facility supporting radiopharmaceutical CRDMO and contract manufacturing services.
C-Ray Therapeutics, a radiopharmaceutical Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has achieved Full Accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). The accreditation is awarded to organizations that demonstrate compliance with international standards in laboratory animal care and research ethics.
The accreditation applies to C-Ray’s 28,000-square-meter integrated facility, which combines AAALAC-accredited preclinical capabilities with cGMP contract manufacturing under China’s Class A Radiation Safety License. The license enables work with more than 30 radioisotopes, including alpha-emitters such as Actinium-225.
According to the company, AAALAC Full Accreditation followed a voluntary evaluation process that included on-site assessments, documentation reviews, and verification of compliance with the Guide for the Care and Use of Laboratory Animals and related guidelines.
“AAALAC accreditation removes a key barrier for Western partners who want to leverage China’s speed and cost advantages but need assurance on quality and ethics.”
Haitao Qiao, General Manager of C-Ray Therapeutics
C-Ray reported that it has delivered more than 70 CRDMO projects to date, including 50 preclinical and molecular imaging CRO projects and 24 CDMO projects. The company stated that it has supported five programs through IND and IND-enabling stages, facilitated 16 investigator-initiated trials, and enabled three clinical supply programs, with two advancing to Phase III clinical studies. The company has raised over $187 million to support continued investment in infrastructure, isotope supply chain partnerships, and regulatory expertise.
